Half-year report · HY

Period2026-01-01 → 2026-06-30
Filed2026-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.22T2026-01-01 → 2026-06-30Cons.Revenue IFRS
Revenue¥2.43T2025-01-01 → 2025-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.14T2025-01-01 → 2025-06-30Cons.Revenue IFRS
Operating income¥129.0bn2026-01-01 → 2026-06-30Cons.Operating profit loss IFRS
Operating income¥68.7bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Profit before tax¥150.9bn2026-01-01 → 2026-06-30Cons.Profit loss before tax IFRS
Profit before tax¥237.9bn2025-01-01 → 2025-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥83.8bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥101.7bn2026-01-01 → 2026-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥147.5bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥52.8bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥116.1bn2026-01-01 → 2026-06-30Cons.Profit loss IFRS
Net income¥60.5bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Total assets¥3.40Tat 2026-06-30Cons.Assets IFRS
Total assets¥3.49Tat 2025-12-31Cons.Assets IFRS
Total assets¥3.30Tat 2025-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.72Tat 2026-06-30Cons.Liabilities IFRS
Total liabilities¥1.90Tat 2025-12-31Cons.Liabilities IFRS
Net assets / equity¥1.68Tat 2026-06-30Cons.Equity IFRS
Net assets / equity¥1.60Tat 2025-12-31Cons.Equity IFRS
Net assets / equity¥1.41Tat 2025-06-30Cons.Equity IFRS
Net assets / equity¥1.53Tat 2024-12-31vCons.Equity IFRS
Equity (owners)¥1.36Tat 2026-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.29Tat 2025-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.12Tat 2025-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥168.1bnat 2026-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥125.3bnat 2025-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥132.4bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.6bnat 2024-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow¥137.3bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥295.4bn2025-01-01 → 2025-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥67.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥53.7bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥185.0bn2025-01-01 → 2025-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥61.6bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥162.5bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥110.5bn2025-01-01 → 2025-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥35.8bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥126.332026-01-01 → 2026-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥182.132025-01-01 → 2025-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥65.232025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥182.132025-01-01 → 2025-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥65.222025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio40.0%at 2026-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio36.8%at 2025-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio34.0%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2026-01-01 → 2026-06-30¥46.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2026-01-01 → 2026-06-30¥12.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2026-01-01 → 2026-06-30¥33.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2026-01-01 → 2026-06-30−¥1.5bn
Reconciling Itemsreconcilingrevenue2026-01-01 → 2026-06-30−¥38.9bn
Reconciling Itemsreconcilingrevenue intersegment2026-01-01 → 2026-06-30−¥38.9bn
Reconciling Itemsreconcilingsegment profit2026-01-01 → 2026-06-30−¥34.2bn
Alcoholic Beveragesreportable segmentrevenue2026-01-01 → 2026-06-30¥519.1bn
Alcoholic Beveragesreportable segmentrevenue external2026-01-01 → 2026-06-30¥517.8bn
Alcoholic Beveragesreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥1.3bn
Alcoholic Beveragesreportable segmentsegment profit2026-01-01 → 2026-06-30¥62.1bn
Health Sciencereportable segmentrevenue2026-01-01 → 2026-06-30¥131.1bn
Health Sciencereportable segmentrevenue external2026-01-01 → 2026-06-30¥128.8bn
Health Sciencereportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥2.3bn
Health Sciencereportable segmentsegment profit2026-01-01 → 2026-06-30¥10.4bn
Non Alcoholic Beveragesreportable segmentrevenue2026-01-01 → 2026-06-30¥296.7bn
Non Alcoholic Beveragesreportable segmentrevenue external2026-01-01 → 2026-06-30¥294.9bn
Non Alcoholic Beveragesreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥1.8bn
Non Alcoholic Beveragesreportable segmentsegment profit2026-01-01 → 2026-06-30¥31.0bn
Pharmaceuticalsreportable segmentrevenue2026-01-01 → 2026-06-30¥263.6bn
Pharmaceuticalsreportable segmentrevenue external2026-01-01 → 2026-06-30¥263.5bn
Pharmaceuticalsreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥139m
Pharmaceuticalsreportable segmentsegment profit2026-01-01 → 2026-06-30¥60.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2025-01-01 → 2025-06-30¥47.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2025-01-01 → 2025-06-30¥14.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2025-01-01 → 2025-06-30¥32.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2025-01-01 → 2025-06-30−¥591m
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥38.3bn
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥38.3bn
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥30.0bn
Alcoholic Beveragesreportable segmentrevenue2025-01-01 → 2025-06-30¥493.8bn
Alcoholic Beveragesreportable segmentrevenue external2025-01-01 → 2025-06-30¥492.6bn
Alcoholic Beveragesreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥1.2bn
Alcoholic Beveragesreportable segmentsegment profit2025-01-01 → 2025-06-30¥53.2bn
Health Sciencereportable segmentrevenue2025-01-01 → 2025-06-30¥129.7bn
Health Sciencereportable segmentrevenue external2025-01-01 → 2025-06-30¥127.2bn
Health Sciencereportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥2.5bn
Health Sciencereportable segmentsegment profit2025-01-01 → 2025-06-30¥8.6bn
Non Alcoholic Beveragesreportable segmentrevenue2025-01-01 → 2025-06-30¥273.4bn
Non Alcoholic Beveragesreportable segmentrevenue external2025-01-01 → 2025-06-30¥271.8bn
Non Alcoholic Beveragesreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥1.6bn
Non Alcoholic Beveragesreportable segmentsegment profit2025-01-01 → 2025-06-30¥29.5bn
Pharmaceuticalsreportable segmentrevenue2025-01-01 → 2025-06-30¥230.7bn
Pharmaceuticalsreportable segmentrevenue external2025-01-01 → 2025-06-30¥230.5bn
Pharmaceuticalsreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥156m
Pharmaceuticalsreportable segmentsegment profit2025-01-01 → 2025-06-30¥33.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 869
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任 あずさ監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese) 神 塚   勲
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese) 佐々木 雅 広
Cpa3 audit firm1 consolidatedFilingDateInstant
Original text (Japanese) 中 村 大 輔
Number of submissionFilingDateInstant1
Revenue IFRS (5-year summary)Prior1InterimDuration1136309000000JPY
Revenue IFRS (5-year summary)InterimDuration1217876000000JPY
Revenue IFRS (5-year summary)Prior1YearDuration2433363000000JPY
Profit loss before tax IFRS (5-year summary)Prior1InterimDuration83761000000JPY
Profit loss before tax IFRS (5-year summary)InterimDuration150855000000JPY
Profit loss before tax IFRS (5-year summary)Prior1YearDuration237859000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1InterimDuration52835000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)InterimDuration101720000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YearDuration147542000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1InterimDuration-700000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)InterimDuration139242000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YearDuration194341000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1InterimInstant1121720000000JPY
Equity attributable to owners of parent IFRS (5-year summary)InterimInstant1361975000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1YearInstant1286991000000JPY
Total assets IFRS (5-year summary)Prior1InterimInstant3301300000000JPY
Total assets IFRS (5-year summary)InterimInstant3401276000000JPY
Total assets IFRS (5-year summary)Prior1YearInstant3494043000000JPY
Basic earnings loss per share IFRS (5-year summary)Prior1InterimDuration65.23
Basic earnings loss per share IFRS (5-year summary)InterimDuration126.33
Basic earnings loss per share IFRS (5-year summary)Prior1YearDuration182.13
Diluted earnings loss per share IFRS (5-year summary)Prior1InterimDuration65.22
Diluted earnings loss per share IFRS (5-year summary)InterimDuration-
Diluted earnings loss per share IFRS (5-year summary)Prior1YearDuration182.13
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1InterimInstant0.340
Ratio of owners equity to gross assets IFRS (5-year summary)InterimInstant0.400
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1YearInstant0.368
Cash flows from used in operating activities IFRS (5-year summary)Prior1InterimDuration67253000000JPY
Cash flows from used in operating activities IFRS (5-year summary)InterimDuration137349000000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior1YearDuration295428000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1InterimDuration-61556000000JPY
Cash flows from used in investing activities IFRS (5-year summary)InterimDuration53663000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YearDuration-185019000000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1InterimDuration35825000000JPY
Cash flows from used in financing activities IFRS (5-year summary)InterimDuration-162473000000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YearDuration-110524000000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1InterimInstant132408000000JPY
Cash and cash equivalents IFRS (5-year summary)InterimInstant168075000000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1YearInstant125292000000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember816000000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember816000000
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant816000000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant816000000
Number of shares heldInterimInstant_No1MajorShareholdersMember128016000

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-12-31pass rounding
balance sheet identityconsolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2026-01-01/2026-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2026-01-01/2026-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsconsolidated 2026-06-30pass